Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Learn

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

  • December 11, 2024
Read More

Study on Anti-Inflammation by Modulation of Endocannabinoid System

  • December 10, 2024
Read More

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

  • September 4, 2024
Read More

Article in Fierce Biotech: The Evolving Alzheimer’s Disease Landscape

  • August 26, 2024
Read More

What is Neuritogenesis? How does Neuritogenesis Affect Alzheimer’s Disease?

  • August 16, 2024
Read More

Article: InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

  • July 25, 2024
Read More

InMed’s INM-901 for Alzheimer’s Disease – Preclinical Data Summary

  • July 25, 2024
Read More

Article: InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease

  • July 22, 2024
Read More

InMed Presents at Benzinga’s Healthcare and Biotech Breakthroughs

  • July 2, 2024
Read More

Replay: InMed Presents at Emerging Growth Conference

  • June 14, 2024
Read More

Article: InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Degenerative Diseases

  • June 14, 2024
Read More

Video Presentation: InMed’s INM-901 is a Potential Multi-factorial Approach to Treating Alzheimer’s Disease

  • June 12, 2024
Read More
123456789101112
123456789101112

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*